First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody.
Laura Kist de RuijterJahlisa S Hooiveld-NoekenDanique GiesenMarjolijn N Lub-de HoogeIris C KokAdrienne H BrouwersSjoerd G EliasMargaret T L NguyenHong LuJourik A GietemaMathilde JalvingDerk J A de GrootOlga VasiljevaElisabeth G E de VriesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
89Zr-CX-072 showed tumor uptake, even in lesions with ≤1% PD-L1 expression, and modest uptake in normal lymphoid organs, with no unexpected uptake in other healthy tissues.